MedTrace Logo

Resistance Rates and Mechanisms of Resistance to Imipenem and Meropenem at UPMC

NCT00443885 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2018-06-12

No results posted yet for this study

Summary

The isolate samples will be collected over a period of one year once IRB approval has been obtained. These isolates were collected as part of the patient's clinical care and once all clinical testing is complete, all isolates will be discarded. The honest broker of our area will collect the isolates and deidentify all information once all clinical testing is complete. The isolates will be obtained from the microbiology lab.

Conditions

  • Gram Negative Organism

Sponsors & Collaborators

  • University of Pittsburgh

    lead OTHER

Principal Investigators

  • Brian Potoski, Pharm D · University of Pittsburgh

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-02-28
Primary Completion
2017-01-31
Completion
2017-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00443885 on ClinicalTrials.gov